ADVENTRX Pharmaceuticals to Host Conference Call and Webcast Discussion of Second Quarter 2007 Results on August 3, 2007
July 26 2007 - 6:00AM
PR Newswire (US)
SAN DIEGO, July 26 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX), a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases,
today announced that it intends to report the Company's second
quarter 2007 financial results via press release after the
financial markets close on Friday, August 3, 2007. Following the
announcement, Evan M. Levine, Chief Executive Officer, and Gregory
P. Hanson, Senior Vice President and Chief Financial Officer, are
scheduled to host a conference call and webcast discussion of the
results and provide a general corporate update. Other members of
ADVENTRX's executive management team will also be available to take
investor questions. Access to the event can be obtained as follows:
Live access on Friday, August 3, 2007, 1:30 p.m. Pacific Time /
4:30 p.m. Eastern Time: -- Telephone (877) 704-5384 (domestic) or
(913) 312-1297 (international) -- The webcast will be available
live by accessing ADVENTRX's website at http://www.adventrx.com/
under "Investors" Replay access: -- Telephone replay will be
available through September 3, 2007 by dialing (888) 203-1112 and
entering the passcode 7724051 -- Replays of the webcast will be
available through September 3, 2007 by accessing ADVENTRX's website
at http://www.adventrx.com/ under "Investors" About ADVENTRX
Pharmaceuticals ADVENTRX Pharmaceuticals is a biopharmaceutical
research and development company focused on commercializing
proprietary product candidates for the treatment of cancer and
infectious diseases. The Company seeks to improve the performance
and safety of existing treatments by addressing significant
problems, such as drug metabolism and bioavailability, excessive
toxicity and treatment resistance. The Company's lead product
candidate, ANX-510 (CoFactor), is in Phase 3 and Phase 2b clinical
trials for the treatment of metastatic colorectal cancer, as well
as in a Phase 2 clinical trial for the treatment of advanced breast
cancer. More information can be found on ADVENTRX's web site at
http://www.adventrx.com/. Forward Looking Statement ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they
materialize or do not prove to be accurate, could cause ADVENTRX's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These
potential risks and uncertainties include, but are not limited to:
the risk that ADVENTRX will be unable to raise sufficient capital
to fund the projects necessary to meet its anticipated or stated
goals and milestones; the potential to attract a strategic partner
and the terms of any related transaction; the ability to timely
enroll subjects in ADVENTRX's current and anticipated clinical
trials; the potential for CoFactor and ADVENTRX's other product
candidates to receive regulatory approval for one or more
indications on a timely basis or at all, and the uncertain process
of seeking regulatory approval; other difficulties or delays in
developing, testing, manufacturing and marketing of and obtaining
regulatory approval for CoFactor or ADVENTRX's other product
candidates; the potential for regulatory authorities to require
additional preclinical work or other clinical requirements to
support regulatory filings; the scope and validity of patent
protection for CoFactor and ADVENTRX's other product candidates;
and other risks and uncertainties more fully described in
ADVENTRX's press releases and periodic filings with the Securities
and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. ADVENTRX assumes no obligation to revise or
update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising
after the date on which it was made. DATASOURCE: ADVENTRX
Pharmaceuticals, Inc. CONTACT: Ioana C. Hone of ADVENTRX
Pharmaceuticals, Inc., +1-858-552-0866 Web site:
http://www.adventrx.com/ Company News On-Call:
http://www.prnewswire.com/comp/920134.html
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024